Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IMA401 (Phase Ia)
IMA401 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Dose-Finding IMA401 TCER® Monotherapy (Phase Ia) | EXPERIMENTAL | Dose-Finding Escalation/De-escalation with IMA401 TCER® (Phase Ia) |
| Dose-Finding Combination Therapy with IMA401 TCER® and Pembrolizumab (Phase Ia) | EXPERIMENTAL | Dose-Finding Escalation/De-escalation of combination therapy with IMA401 TCER and pembrolizumab (Phase Ia) |
| Extension IMA401 TCER® Monotherapy (Phase Ib) | EXPERIMENTAL | IMA401 monotherapy extension cohort following the determination of the recommended dose for extension (RDE) (Phase Ib) |
| Name | Type | Description |
|---|---|---|
| IMA401 (Phase Ia) | BIOLOGICAL | Intravenous infusions in escalating dose levels |
| Pembrolizumab (Phase Ia) | BIOLOGICAL | Intravenous infusions in escalating dose levels for combination of IMA 401 and Pembrolizumab |
| IMA 401 (Phase Ib) | BIOLOGICAL | Treatment at recommended dose for extension (RDE) |
Inclusion Criteria: * Patients must have voluntarily signed a written ICF, be able to understand and comply with clinical trial procedures * Patients ≥ 18 years old * Patients must have pathologically confirmed and documented advanced and/or metastatic NSCLC or HNSCC, other solid tumor may be consi...
Top 2 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
IMA401 is an investigational monoclonal antibody being developed for the treatment of refractory cancer, including recurrent and refractory solid tumors in adults. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
IMA401 targets MAGEA4/8, a tumor-associated antigen. As a T cell engaging receptor (TCER) bispecific antibody, it is designed to redirect T cells to recognize and attack cancer cells expressing MAGEA4/8.
IMA401 is being developed by Immatics N.V., a biopharmaceutical company listed on the stock exchange under the ticker symbol IMTX. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy.
IMA401 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied in clinical trials to assess its safety and potential effectiveness in patients with refractory cancer.
IMA401 is being evaluated in a Phase 1 clinical trial with the identifier NCT05359445. This trial is studying IMA401 alone or in combination with a checkpoint inhibitor in patients with recurrent and/or refractory solid tumors. The trial is active but not recruiting participants.
Yes, IMA401 is also referred to as IMA401 (Phase Ia). This alternative name reflects the specific phase of clinical development for this investigational therapy. Both names refer to the same drug candidate being developed by Immatics N.V.